Basel Medical Resolves Nasdaq Filing Deficiency After March 13 Form 20-F Submission
Basel Medical filed an amended Form 20-F for fiscal 2025 on March 13, 2026, and Nasdaq staff confirmed compliance with Listing Rule 5250(c)(1). The resolution closes the prior periodic filing deficiency, reinstating the Company’s standing on The Nasdaq Stock Market.
1. Nasdaq Confirms Compliance
Nasdaq staff reviewed Basel Medical’s amended annual report on Form 20-F for fiscal year 2025, filed on March 13, 2026, and determined the Company now meets the periodic filing requirement under Listing Rule 5250(c)(1).
2. Details of the Amended Form 20-F
The amended Form 20-F addressed discrepancies in the initial filing, providing updated financial statements and disclosures to satisfy Nasdaq’s criteria for timely periodic reports.
3. Resolution of Prior Deficiency
With Nasdaq’s notification, the prior deficiency under the Periodic Filing Rule has been fully resolved, eliminating the risk of potential delisting proceedings related to late filings.
4. Implications for Basel Medical
Compliance reinstates Basel Medical’s full standing on The Nasdaq Stock Market, reducing regulatory uncertainty and potentially bolstering investor confidence in the Company’s governance and reporting practices.